Loading stock data…
Azitra (AZTR)
$0.17-0.01 (-4.18%)
Market ClosedLast close Sep 8
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Azitra, Inc. in the Healthcare sector is trading at $0.17 with a market capitalization of $3M. Wall Street consensus targets $0.78 (2 analysts), implying a +350.6% move over the next 12 months. The stock is currently near its 52-week low of $0.10, remaining 21.8% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 73 is overbought against a weak tape. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +350.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 73 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.93M↓ | -$2.23M↑ | -$2.77M↑ | -$2.87M↑ | -$3.10M |
| Net Income | -$3.93M↓ | -$2.23M↑ | -$2.76M↑ | -$2.89M↑ | -$3.07M |
Peer Comparison
JNJUNHPFE
Fundamentals
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.91M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-112.73%
Volume
Today's trading volume
242,375